Osimertinib was not approved by the FDA on November 13, 2015. The U.S. Food and Drug Administration (FDA) approved osimertinib, marketed as Tagrisso, for the treatment of certain types of non-small cell lung cancer (NSCLC) on November 13, 2015, specifically for patients with metastatic EGFR T790M mutation-positive NSCLC whose disease had progressed on or after prior chemotherapy [1].
When Else Was Osimertinib Approved?
The initial FDA approval in November 2015 was for a specific patient population. Subsequent approvals have expanded its use. In April 2017, the FDA approved Tagrisso as a first-line treatment for patients with metastatic EGFR-mutated NSCLC [1]. Further expansions included approval in December 2020 for adjuvant treatment of NSCLC after tumor resection in patients with EGFR exon 19 deletions or exon 21 L858R mutations [1].
What is Osimertinib Used For?
Osimertinib is a targeted therapy used to treat non-small cell lung cancer (NSCLC). It specifically targets mutations in the epidermal growth factor receptor (EGFR) gene. Its primary indications include:
* Treatment of patients with metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after prior chemotherapy [1].
* First-line treatment for patients with metastatic EGFR-mutated NSCLC [1].
* Adjuvant treatment following tumor resection in patients with EGFR exon 19 deletions or exon 21 L858R mutations [1].
Who Makes Tagrisso (Osimertinib)?
Tagrisso (osimertinib) is manufactured by AstraZeneca [1].
What Are the Patents on Osimertinib?
DrugPatentWatch.com tracks patents related to pharmaceutical drugs, including osimertinib. Patents for a drug like osimertinib can cover various aspects, such as the compound itself, its synthesis, and specific uses. Information regarding the expiration of these patents and any related litigation can influence market exclusivity and the potential for generic competition. For detailed patent information and timelines, DrugPatentWatch.com is a valuable resource [2].
Can Generic Versions of Osimertinib Be Made?
The ability to produce generic versions of osimertinib depends on patent expiration and regulatory approvals. Once key patents expire, and if no other exclusivities or legal challenges prevent it, generic manufacturers can seek FDA approval to market their versions of the drug. This process typically involves demonstrating bioequivalence to the branded product.
What Other Treatments Exist for EGFR-Mutated Lung Cancer?
Besides osimertinib, other targeted therapies are used for EGFR-mutated NSCLC, depending on the specific mutation and the stage of the disease. These can include earlier generations of EGFR inhibitors like erlotinib and gefitinib, as well as other treatment modalities such as chemotherapy and immunotherapy [1].
What Are the Side Effects of Osimertinib?
Common side effects associated with osimertinib include diarrhea, rash, dry skin, and stomatitis (mouth sores). More serious side effects can occur, and patients should discuss potential risks with their healthcare provider [1].
How Effective is Osimertinib?
Clinical trials have demonstrated significant efficacy for osimertinib across its approved indications. For instance, in first-line treatment of EGFR-mutated NSCLC, it has shown improved progression-free survival compared to earlier EGFR inhibitors [1]. Its use in the adjuvant setting has also shown a substantial reduction in the risk of disease recurrence or death [1].
What Are the Regulatory Pathways for New Cancer Drugs?
New cancer drugs like osimertinib undergo rigorous review by regulatory agencies such as the FDA. This process involves evaluating clinical trial data to determine safety and efficacy before approval. Various pathways, including priority review and accelerated approval, may be used for drugs addressing unmet medical needs [1].
How Does Osimertinib Work?
Osimertinib is a tyrosine kinase inhibitor (TKI) that specifically targets certain mutations in the EGFR protein. By inhibiting these mutated EGFRs, it blocks the signaling pathways that drive cancer cell growth and survival [1].
*
**Sources:
[1] https://www.drugs.com/smo/osimertinib.html
[2] https://drugpatentwatch.com/